全基因组表观遗传Meta 分析鉴定与糖尿病肾病相关的 DNA 甲基化生物标志物。
Epigenome-wide meta-analysis identifies DNA methylation biomarkers associated with diabetic kidney disease.
机构信息
Molecular Epidemiology Research Group, Centre for Public Health, Queen's University Belfast, Belfast, UK.
Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland.
出版信息
Nat Commun. 2022 Dec 22;13(1):7891. doi: 10.1038/s41467-022-34963-6.
Type 1 diabetes affects over nine million individuals globally, with approximately 40% developing diabetic kidney disease. Emerging evidence suggests that epigenetic alterations, such as DNA methylation, are involved in diabetic kidney disease. Here we assess differences in blood-derived genome-wide DNA methylation associated with diabetic kidney disease in 1304 carefully characterised individuals with type 1 diabetes and known renal status from two cohorts in the United Kingdom-Republic of Ireland and Finland. In the meta-analysis, we identify 32 differentially methylated CpGs in diabetic kidney disease in type 1 diabetes, 18 of which are located within genes differentially expressed in kidneys or correlated with pathological traits in diabetic kidney disease. We show that methylation at 21 of the 32 CpGs predict the development of kidney failure, extending the knowledge and potentially identifying individuals at greater risk for diabetic kidney disease in type 1 diabetes.
1 型糖尿病影响全球超过 900 万人，其中约 40%的人患有糖尿病肾病。新出现的证据表明，表观遗传改变，如 DNA 甲基化，与糖尿病肾病有关。在这里，我们评估了英国-爱尔兰共和国和芬兰的两个队列中 1304 名经过精心特征描述的 1 型糖尿病患者和已知肾脏状况的个体与糖尿病肾病相关的血液衍生全基因组 DNA 甲基化差异。在荟萃分析中，我们在 1 型糖尿病的糖尿病肾病中发现了 32 个差异甲基化的 CpG，其中 18 个位于肾脏中差异表达的基因内，或与糖尿病肾病的病理特征相关。我们表明，32 个 CpG 中的 21 个甲基化可预测肾衰竭的发生，这扩展了知识并可能确定 1 型糖尿病中患有糖尿病肾病风险更高的个体。
Zotero 插件